Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential (Q40636649)

22 September 2017

1 reference

title

Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential (English)

1 reference

22 September 2017

1 reference

1 reference

1

Kallenberg CG

1 reference

22 September 2017

Brouwer E

2

1 reference

22 September 2017

Weening JJ

series ordinal

3

1 reference

22 September 2017

Tervaert JW

series ordinal

4

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 July 1994

1 reference

22 September 2017

1 reference

22 September 2017

volume

46

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

1-15

1 reference

Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Diagnosis and management of glomerulonephritis and vasculitis presenting as acute renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Goodpasture antigen of the glomerular basement membrane: localization to noncollagenous regions of type IV collagen

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Crescentic glomerulonephritis without immune deposits: Clinicopathologic features

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Antineutrophil cytoplasmic autoantibodies and associated diseases: a review

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

AN ANTINUCLEAR FACTOR SPECIFIC FOR LEUCOCYTES

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Granulocyte-specific antinuclear antibodies. Possible significance for the pathogenesis, clinical features and diagnosis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Cloning of cDNA for proteinase 3: a serine protease, antibiotic, and autoantigen from human neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Substrate and inhibitor studies on proteinase 3

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Determination of proteinase 3-alpha 1-antitrypsin complexes in inflammatory fluids

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Interference of Wegener's granulomatosis autoantibodies with neutrophil Proteinase 3 activity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Reactivity of antineutrophil cytoplasmic autoantibodies with mononuclear phagocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

A human renal cancer line as a new antigen source for the detection of antibodies to cytoplasmic and nuclear antigens in sera of patients with Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Detection and quantitation of anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis by ELISA using affinity-purified antigen

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Association of autoantibodies to myeloperoxidase with different forms of vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Tissue destruction by neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Autoantibodies to native myeloperoxidase in patients with pulmonary hemorrhage and acute renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Sequence homologies between hsp60 and autoantigens

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Antilactoferrin antibody in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Clinical significance of antineutrophil cytoplasmic autoantibodies with specificity for lactoferrin in renal diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

ANCA and associated diseases: immunodiagnostic and pathogenetic aspects

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Is p-ANCA in ulcerative colitis directed against beta-glucuronidase?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Alpha-enolase: a novel cytosolic autoantigen in ANCA positive vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Detection of autoantibodies against myeloid lysosomal enzymes: A useful adjunct to classification of patients with biopsy-proven necrotizing arteritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Antimyeloperoxidase antibodies in the Churg-Strauss syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

IgA antineutrophil cytoplasmic antibody in Henoch-Schönlein purpura

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-myeloperoxidase antibodies: Immunological characteristics and clinical associations

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Detection of anti-myeloperoxidase and anti-elastase antibodies in vasculitides and infections

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Fluorescent antiglobulin studies in leukopenic and related disorders

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-neutrophil cytoplasmic antibodies in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-neutrophil cytoplasmic autoantibodies in patients with symptomatic HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Antineutrophil cytoplasmic antibodies, cystic fibrosis, and infection

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Relevance of classic anti-neutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-alpha 1-antitrypsin complexation to disease activity in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Predominance of IgGl and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

The effect of anti-neutrophil cytoplasm autoantibodies on the signal transduction in human neutrophils

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-neutrophil cytoplasm antibodies (ANCA) increase neutrophil adhesion to cultured human endothelium

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Neutrophil activation in vitro and in vivo in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Clinical and immunological follow-up of patients with severe renal disease in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Serum markers of T cell activation in relapses of Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Cyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Infectious complications of cyclophosphamide treatment for vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Cyclophosphamide-induced bladder toxicity in wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

NIH conference. Lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Relapses in Wegener's granulomatosis: the role of infection

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Treatment of systemic vasculitis with pooled intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Monoclonal-Antibody Therapy in Systemic Vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.239

7 January 2021

Identifiers

DOI

10.1038/KI.1994.239

1 reference

22 September 2017

1 reference